Study protocol for a multicentre, randomised, controlled trial to assess the effectiveness of antimicrobial central venous catheters versus ordinary central venous catheters at reducing catheter related infections in critically ill Chinese patients

Minming Wu, Yao Chen, Bin Du, Yan Kang, Minming Wu, Yao Chen, Bin Du, Yan Kang

Abstract

Introduction: Catheter use is associated with many complications and is an iatrogenic source of morbidity and mortality in intensive care units (ICU). The catheter being studied (Certofix Protect) was developed to reduce the risk of catheter related infections. This clinical trial will compare the safety and efficiency of Certofix Protect with that of an ordinary Certofix catheter.

Methods and analysis: In this multicentre trial, we will randomly assigned dual lumen central venous catheterisation (≥5 ds) in patients in the adult ICU to the antimicrobial central venous catheter (CVC) group or the ordinary CVC group. We plan to recruit 12-16 medical centres in China. Our main objective is to assess the effectiveness of antimicrobial CVCs in reducing catheter related bloodstream infection (CRBSI), all cause mortality, catheter colonisation, catheter related thrombosis and other catheter related complications. The primary outcome is the incidence of CRBSI.

Ethics and dissemination: The ethics committee of West China Hospital of Sichuan University has granted ethics approval for this study (27 January 2015). The results will be published in peer reviewed journals and presented at conferences.

Trial registration number: NCT02645682.

Keywords: catheter related infection; central venous catheterization; multi-center randomized controlled trial.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. O’Grady NP, Alexander M, Burns LA, et al. . Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2011;39(Suppl 1):S1–34. 10.1016/j.ajic.2011.01.003
    1. Cicalini S, Palmieri F, Petrosillo N. Clinical review: new technologies for prevention of intravascular catheter-related infections. Crit Care 2004;8:157–62. 10.1186/cc2380
    1. Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? Infect Control Hosp Epidemiol 2000;21:375–80. 10.1086/501776
    1. Rupp ME. Central venous catheters coated or impregnated with antimicrobial agents effectively prevent microbial colonisation and catheter-related bloodstream infections. Evid Based Med 2014;19:56 10.1136/eb-2013-101471
    1. Halton KA, Cook DA, Whitby M, et al. . Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Crit Care 2009;13:R35 10.1186/cc7744
    1. Lai NM, Chaiyakunapruk N, Lai NA. Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults. Cochrane Database Syst Rev 2013;6:CD007878.
    1. Maki DG, Stolz SM, Wheeler S, et al. . Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997;127:257–66. 10.7326/0003-4819-127-4-199708150-00001
    1. Raad I, Darouiche R, Dupuis J, et al. . Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997;127:267–74.
    1. Rupp ME, Lisco SJ, Lipsett PA, et al. . Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 2005;143:570–80. 10.7326/0003-4819-143-8-200510180-00007
    1. Gong P, Li H, He X, et al. . Preparation and antibacterial activity of Fe3O4 and Ag nanoparticles. Nanotechnology 2007;18:604–11.
    1. Shrivastava S, Bera T, Roy A, et al. . Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology 2007;18:225103–12. 10.1088/0957-4484/18/22/225103
    1. Samuel U, Guggenbichler JP. Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int J Antimicrob Agents 2004;23(Suppl 1):75–8. 10.1016/j.ijantimicag.2003.12.004
    1. Hsu SH, Tseng HJ, Lin YC. The biocompatibility and antibacterial properties of waterborne polyurethane-silver nanocomposites. Biomaterials 2010;31:6796–808. 10.1016/j.biomaterials.2010.05.015
    1. Mehall JR, Saltzman DA, Jackson RJ, et al. . Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002;30:908–12. 10.1097/00003246-200204000-00033
    1. Campisi C, Biffi R, Pittiruti M. Catheter-related central venous thrombosis: the development of a nationwide consensus paper in Italy. J Assoc Vasc Access 2007;12:38–46. 10.2309/java.12-1-10
    1. Cortelezzi A, Moia M, Falanga A, et al. . Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005;129:811–7. 10.1111/j.1365-2141.2005.05529.x
    1. Monreal M, Raventos A, Lerma R, et al. . Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost 1994;72:548–50.
    1. Kearon C, Akl EA, Comerota AJ, et al. . Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl 2):e419S–94. 10.1378/chest.11-2301
    1. Raad II, Luna M, Khalil SA, et al. . The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994;271:1014–6. 10.1001/jama.1994.03510370066034
    1. Pierce CM, Wade A, Mok Q, et al. . Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000;26:967–72. 10.1007/s001340051289
    1. 中华医学会重症医学分会。血管内导管相关感染的预防与治疗指南。中国实用外科杂志. 2008; 28: 413-21
    1. Parienti JJ, Mongardon N, Mégarbane B, et al. . Intravascular complications of central venous catheterization by insertion site. N Engl J Med 2015;373:1220–9. 10.1056/NEJMoa1500964
    1. Adsit D. What the call center industry can learn from manufacturing: Part II (PDF): National Association of Call Centers, 2007. (Retrieved 21 Dec 2012).
    1. Phillips J. The project management hut. “Quality control in project management”, 2008. (Retrieved 21 Dec 2012).

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere